We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

Back to rankings

75 hedge funds and large institutions have $197M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 8

65% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 17

57% more capital invested

Capital invested by funds: $125M → $197M (+$71.7M)

56% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $665K

34% more funds holding

Funds holding: 56 → 75 (+19)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
75
Holders Change
+19
Holders Change %
+33.93%
% of All Funds
1.71%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
28
Reduced
17
Closed
8
Calls
$1.04M
Puts
$665K
Net Calls
+$374K
Net Calls Change
+$296K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$11.4M
2
O
OrbiMed
New York
+$6.61M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.61M
4
Franklin Resources
Franklin Resources
California
+$4.73M
5
Millennium Management
Millennium Management
New York
+$4.68M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.59M
2
GPP
Great Point Partners
Connecticut
-$4.3M
3
DCM
Driehaus Capital Management
Illinois
-$3M
4
DM
Deerfield Management
New York
-$2.51M
5
VC
Vivo Capital
California
-$2.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
26
Monashee Investment Management
Massachusetts
$1.72M – – –
EP
27
Eversept Partners
New York
$1.57M +$951K +166,317 +155%
DM
28
Deerfield Management
New York
$1.34M -$2.51M -439,257 -65%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$1.3M +$985K +172,248 +320%
Baillie Gifford & Co
30
Baillie Gifford & Co
United Kingdom
$1.26M – – –
HP
31
Hound Partners
New York
$1.12M +$1.12M +194,913 New
OAM
32
Oxford Asset Management
United Kingdom
$1.09M +$1.09M +190,653 New
MCM
33
Moore Capital Management
New York
$860K +$858K +150,000 New
Wells Fargo
34
Wells Fargo
California
$761K +$183K +32,013 +32%
JGC
35
J. Goldman & Co
New York
$596K +$595K +104,000 New
UOC
36
UBS O'Connor
Illinois
$583K +$582K +101,800 New
AIM
37
ARK Investment Management
Florida
$572K -$36.3K -6,342 -6%
Walleye Trading
38
Walleye Trading
New York
$561K +$561K +97,986 New
Squarepoint
39
Squarepoint
New York
$542K +$541K +94,649 New
OM
40
Opaleye Management
Massachusetts
$521K -$910K -159,000 -64%
SSA
41
Schonfeld Strategic Advisors
New York
$461K +$461K +80,500 New
Walleye Capital
42
Walleye Capital
New York
$364K +$363K +63,456 New
FIM
43
Fernwood Investment Management
Massachusetts
$309K +$309K +54,000 New
Federated Hermes
44
Federated Hermes
Pennsylvania
$287K +$286K +50,000 New
EMG
45
ETF Managers Group
New Jersey
$282K +$281K +49,199 New
QSS
46
Quantitative Systematic Strategies
Florida
$271K +$270K +47,239 New
State Street
47
State Street
Massachusetts
$268K +$267K +46,700 New
GC
48
Grace Capital
Massachusetts
$228K +$229K +40,000 New
RJA
49
Raymond James & Associates
Florida
$215K -$24.6K -4,300 -10%
TI
50
Trexquant Investment
Connecticut
$200K +$135K +23,515 +206%
1
2
3 4

FOMX Hedge Fund Activity: Q3 2018 in Review

75 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2018, worth a combined $197M — up 57% from $125M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new FOMX positions and 8 closed out — a net gain of 19 holders — while 28 added to existing stakes and 17 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $11.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.59M.

  • 75 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2018, up from 56 in Q2 2018.
  • Funds reported $197M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2018, up 57% quarter-over-quarter.
  • 27 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2018 and 8 closed out, a net change of +19 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2018 was Perceptive Advisors, an estimated $11.4M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2018 was Baker Bros. Advisors, an estimated $4.59M sold.

Based on aggregated 13F filings for Q3 2018.